At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 48 enrolled
Drug / intervention
erlotinib hydrochloridedrug
Likely dose
erlotinib hydrochloride 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Erlotinib (TarcevaTM) Combined With Chemoradiation and Adjuvant Chemotherapy in Patients With Resectable Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Apr 12, 2006·Updated Jun 4, 2020
In Brief
A Phase 2 clinical trial evaluating erlotinib hydrochloride for Pancreatic Cancer. Completed, enrolled 48 participants across 1 site.
Detailed Summary
To seek preliminary evidence of antitumor activity (progression free survival) of Erlotinib in combination with standard adjuvant chemoradiation and chemotherapy in patients with resected adenocarcinoma of the pancreas.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2006
First PostedApr 2006
Primary CompletionDec 2013
Study CompletionFeb 2019
TodayJul 2026
First PostedApr 12, 2006
Enrollment StartMar 16, 2006
Primary CompletionDec 27, 2013
Study CompletionFeb 27, 2019
TodayJul 2, 2026
Enrollment to primary: 7.8 yearsPosted 20.2 years ago
Interventions
erlotinib hydrochloridedrug
Erlotinib 100 mg PO QD (1 hour prior to Capecitabine) (both given daily without interruption)